Published on: May 2022
The global domination of Mesenchymal Stem Cells market
The global market for mesenchymal stem cells was valued at USD 2.4 billion in 2020, and it is predicted to increase at a CAGR of 12.6 percent between 2021 and 2028. The market is growing due to an increase in mesenchymal stem cell (MSC)-based research and its implications in the field of regenerative medicine. The ever-changing environment of stem cell therapies is projected to drive investment in the MSC market; large-scale operational entities are pursuing small or emerging competitors with an acquisition strategy to expand their market position.
The Market Landscape for Mesenchymal Stem Cells
The market is expected to develop faster due to a robust pipeline of mesenchymal stem cell-based products and increasing applications of mesenchymal stem cells. Regulatory organisations throughout the world have approved ten products based on mesenchymal stem cells as of 2019. Furthermore, a large number of businesses are investigating the potential of MSCs as therapies for the treatment of inflammatory illnesses, which is expected to promote market growth.
Did Covid-19 leave an impact on the Mesenchymal Stem Cells market?
MSCs are being used in a Takeda/TiGenix phase 3 clinical trial for complicated perianal fistulas in Crohn's Disease. As of September 2020, this is the most successful late-stage clinical trial. These factors are expected to increase the use of MSC goods offered by main market players, resulting in increased market competition. The current COVID-19 pandemic has shifted the focus of the scientific community and industry actors to MSC-based therapies development. MSCs' immunomodulatory properties make them a promising treatment option for COVID-19-related respiratory infections.
The Future of Mesenchymal Stem Cells in the global market
More than 50 clinical trials involving MSCs in the development of treatments for SARS-CoV-2 infection have been reported as of July 2020. MSCs are also being used in an increasing number of research projects involving the development of novel vaccine platforms. For example, a group of Chinese researchers presented a novel technique for creating COVID-19 vaccines based on modified human MSCs in June 2020, with promising and good antibody response.
The majority of mesenchymal stem cell uses are focused on research and clinical settings, with commercial applications having a far lower penetration. This is primarily due to the lack of standardised and controlled stem cell therapy administration, as well as ethical and safety concerns about human MSCs. Regulations and standardisation in the mesenchymal stem cell sector must evolve in order to keep the market growing.
Easier said than done, is it? Not anymore. It is as easy as saying because the expert team at Industry Data Analytics does the work for you. Tap on the door to success with the expert report by the Market Insights Reports. contact@industrydataanalytics.com